Compare Tango Therapeutics Inc. (TNGX) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Valero Energy Corporation — how do they compare? Tango Therapeutics Inc. trades at $22.3 (market cap $3.74B), while Valero Energy Corporation trades at $457.88 (market cap $131.43B). The key difference: Valero Energy Corporation is far larger — about 35.1× Tango Therapeutics Inc.'s market cap, and Valero Energy Corporation pays a 1.05% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Valero Energy Corporation for 57 Days on average.
| TNGX | VLO | |
|---|---|---|
Market Cap | $3.74B | $131.43B |
Volume | 3,438,781 | 2,513,030 |
Sector | Health | Energy |
52-Week High | $32.90 | $459.78 |
52-Week Low | $7.50 | $156.39 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $2.76B | $134.90B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Valero Energy (VLO) trades at $456.46, up 4.69% today and near its 52-week high, supported by bullish technical signals and strong earnings beats. The stock exhibits robust profitability with a 29.31% ROE and trades at a P/E of 19.04. Recent news highlights institutional interest and positive refining margins, though revenue has declined from 2022 peaks. Cash flow trends show a rebound projected for 2026, with net cash flow expected to reach $3.3 billion.
The outlook remains positive given analyst consensus and earnings momentum, but risks include volatile energy markets and potential policy impacts on exports. The stock's current price exceeds the consensus target of $417.70, suggesting near-term caution despite long-term growth drivers in refining margins and operational efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
